top of page

AbbVie signs $2.54 billion potential oncology collaboration with DISCO Pharmaceuticals for AND-gated bispecifics

Writer: nuaxia
nuaxia
2 minutes ago
2 min read

AbbVie will combine its oncology development expertise with DISCO's tumour-surface mapping technology to discover selective bispecific therapies, with $40 million payable upfront and further potential milestones.


On 19 November 2026, DISCO Pharmaceuticals announced a research collaboration and option-to-license agreement with AbbVie to discover AND-gated bispecific therapeutics targeting solid tumours, including $40 million in upfront payments.


DISCO may receive up to $2.5 billion in additional option, development and other milestone payments plus tiered royalties, while AbbVie can elect to license selected programmes following specified research activities.

Field

Content

Alert Type

Deal

Companies

AbbVie; DISCO Pharmaceuticals

Deal Type

Strategic research collaboration and option-to-license agreement

Asset or Company

Investigational AND-gated bispecific therapeutics discovered using DISCOtech

Therapy Area(s)

Oncology; solid tumours

Technology or Modality

DISCOtech surfaceome mapping and AND-gated bispecific antibody discovery targeting pairs of tumour-associated cell-surface proteins

Deal Value

$40 million upfront; up to $2.5 billion in additional contingent option, development and other milestone payments; tiered royalties on worldwide net sales. Approximately $2.54 billion in potential upfront and milestone consideration excluding royalties.

Geography

Germany and United States; potential worldwide commercialisation

What Happened

DISCO Pharmaceuticals entered a research collaboration with AbbVie to identify tumour-selective antigen pairs and discover AND-gated bispecific therapeutics. AbbVie may obtain exclusive licences to selected programmes after specified research activities.

Why It Matters

The agreement supports development of investigational therapies designed to recognise combinations of tumour-associated surface proteins rather than relying on a single target, potentially improving selectivity.

Supporting Context

DISCOtech maps tumour-cell surface protein expression to identify pairs suitable for simultaneous recognition. The approach is intended to distinguish tumour cells from healthy tissue displaying only one of the targets.

Strategic Rationale

The collaboration combines DISCO's surfaceome mapping and bispecific discovery platform with AbbVie's oncology research and development capabilities.

Potential Impact

The partnership could advance new solid-tumour programmes if research identifies suitable targets and development candidates demonstrate acceptable safety and efficacy; clinical benefit remains unproven.

Key Takeaway

DISCO secures $40 million upfront and potential milestone payments under an oncology discovery collaboration; the headline transaction value is predominantly contingent rather than guaranteed.

What to Watch

Completion of research activities, AbbVie's decisions on exclusive licensing options, selection of development candidates and subsequent preclinical or clinical progress.

Primary Source

https://discopharma.de/disco-pharmaceuticals-announces-strategic-collaboration/

Relevant Date

19 November 2026


Discover how nuaxia can support your next medical education initiative:

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page